David Cooper (host)

Lorenzo, if only 2% of people with diabetes got insulin, that would be like a national health problem, epidemic, scandal, that kind of thing.

I started this interview with, I think, a mistake a lot of people make, and I kind of lamented.

I started this interview by talking about how Ozempic or GLP-1 drugs were an exciting potential treatment for alcoholism.

But the real fact is there already are drugs that are known to help.

And so the real conversation should be, and I'm glad it's taking this turn.

I'm glad I've sort of made this mistake in real time.

There's kind of like a cultural stigma prescribing problem, not really like a science gap because drugs to help with alcoholism already exist.

I suppose it is exciting that Ozempic GLP-1 drugs could help.

But the real story is like, why aren't people getting the help they need?

So I suppose it's good news that Ozampic GLP-1 drugs are a potential treatment.

It seems like we need clinical trials, of course, but also we got to get the information out and so people can seek treatment if they need it.

Right.

We need them both.

Lorenzo, I appreciate you coming on the show.

This has been a fascinating conversation.

Thank you for your time.

Dr. Lorenzo Leggio is a physician and scientist at the National Institutes of Health.

Up next, 50 seasons, one island, the show Survivor.

Did it just entertain us or did it reinvent TV?

I'm David Cooper.